Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ehsan Ghorani

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Immunity|January 11, 2023
Two faces: IL-22 effects prevail over defense against metastasisChen Qing, Ehsan Ghorani
Hematology/Oncology Clinics of North America|September 25, 2024
Future Directions for Gestational Trophoblastic DiseaseEhsan Ghorani, Michael J Seckl
Journal of Gynecologic Oncology|April 20, 2022
Emergency craniotomy: a life-saving procedure as part of multi-modal therapy of GTNEhsan Ghorani, Michael J Seckl
Science (New York, N.Y.)|February 17, 2018
Chromatin regulation and immune escapeEhsan Ghorani, Sergio A Quezada
Best Practice & Research. Clinical Obstetrics & Gynaecology|June 13, 2021
Progress to international harmonisation of care and future developmentsMichael J Seckl, Ehsan Ghorani
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 6, 2023
Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapyLindsay Hennah, Michael Seckl, Ehsan Ghorani
Immunity|October 11, 2023
Cancer cell-intrinsic mechanisms driving acquired immune toleranceEhsan Ghorani, Charles Swanton, Sergio A Quezada
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 5, 2025
Erratum to 'Controversies in malignant ovarian germ cell tumors' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101670]Michael J Seckl, Baljeet Kaur, Ehsan Ghorani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 28, 2025
Controversies in malignant ovarian germ cell tumorsMichael J Seckl, Baljeet Kaur, Ehsan Ghorani, et al.
Therapeutic Advances in Medical Oncology|November 13, 2023
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?Chii Yang Kuah, Robert Monfries, Matteo Quartagno, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Immunity|January 11, 2023
Two faces: IL-22 effects prevail over defense against metastasisChen Qing, Ehsan Ghorani
Hematology/Oncology Clinics of North America|September 25, 2024
Future Directions for Gestational Trophoblastic DiseaseEhsan Ghorani, Michael J Seckl
Journal of Gynecologic Oncology|April 20, 2022
Emergency craniotomy: a life-saving procedure as part of multi-modal therapy of GTNEhsan Ghorani, Michael J Seckl
Science (New York, N.Y.)|February 17, 2018
Chromatin regulation and immune escapeEhsan Ghorani, Sergio A Quezada
Best Practice & Research. Clinical Obstetrics & Gynaecology|June 13, 2021
Progress to international harmonisation of care and future developmentsMichael J Seckl, Ehsan Ghorani
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 6, 2023
Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapyLindsay Hennah, Michael Seckl, Ehsan Ghorani
Immunity|October 11, 2023
Cancer cell-intrinsic mechanisms driving acquired immune toleranceEhsan Ghorani, Charles Swanton, Sergio A Quezada
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 5, 2025
Erratum to 'Controversies in malignant ovarian germ cell tumors' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101670]Michael J Seckl, Baljeet Kaur, Ehsan Ghorani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 28, 2025
Controversies in malignant ovarian germ cell tumorsMichael J Seckl, Baljeet Kaur, Ehsan Ghorani, et al.
Therapeutic Advances in Medical Oncology|November 13, 2023
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?Chii Yang Kuah, Robert Monfries, Matteo Quartagno, et al.
Pageof 5